Iruplinalkib for locally advanced or metastatic ALK+ NSCLC
Iruplinalkib for locally advanced or metastatic ALK+ NSCLC

Iruplinalkib for locally advanced or metastatic ALK+ NSCLC

Iruplinalkib, a highly selective oral tyrosine kinase inhibitor (TKI) has received approval for treating locally advanced or metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC). Specifically designed for ALK and ROS1 inhibition, Iruplinalkib is indicated for patients progressing after Crizotinib therapy or intolerant to it. This milestone marks a significant advancement in providing therapeutic options for this subset of NSCLC patients.

要查看或添加评论,请登录

Connect2Clinic的更多文章

社区洞察

其他会员也浏览了